NO332618B1 - Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav - Google Patents
Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav Download PDFInfo
- Publication number
- NO332618B1 NO332618B1 NO20013147A NO20013147A NO332618B1 NO 332618 B1 NO332618 B1 NO 332618B1 NO 20013147 A NO20013147 A NO 20013147A NO 20013147 A NO20013147 A NO 20013147A NO 332618 B1 NO332618 B1 NO 332618B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- ctla
- antibodies
- human
- amino acid
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 101
- 108010021064 CTLA-4 Antigen Proteins 0.000 title claims description 239
- 102000008203 CTLA-4 Antigen Human genes 0.000 title claims description 239
- 210000004027 cell Anatomy 0.000 title claims description 125
- 238000000034 method Methods 0.000 title claims description 79
- 239000012634 fragment Substances 0.000 title claims description 47
- 239000000427 antigen Substances 0.000 title claims description 35
- 102000036639 antigens Human genes 0.000 title claims description 35
- 108091007433 antigens Proteins 0.000 title claims description 34
- 150000007523 nucleic acids Chemical class 0.000 title claims description 13
- 102000039446 nucleic acids Human genes 0.000 title claims description 11
- 108020004707 nucleic acids Proteins 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 230000008569 process Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 105
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 238000003556 assay Methods 0.000 claims description 30
- 230000004073 interleukin-2 production Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 230000016396 cytokine production Effects 0.000 claims description 16
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 102000043321 human CTLA4 Human genes 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 238000011830 transgenic mouse model Methods 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 241000282560 Macaca mulatta Species 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000014828 interferon-gamma production Effects 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 27
- 102000018358 immunoglobulin Human genes 0.000 abstract description 27
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 9
- 239000005557 antagonist Substances 0.000 abstract description 5
- 231100000433 cytotoxic Toxicity 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 3
- 101710135378 pH 6 antigen Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 145
- 108090000623 proteins and genes Proteins 0.000 description 89
- 235000001014 amino acid Nutrition 0.000 description 85
- 229940024606 amino acid Drugs 0.000 description 73
- 108090000765 processed proteins & peptides Proteins 0.000 description 73
- 102000004169 proteins and genes Human genes 0.000 description 49
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 44
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 239000002299 complementary DNA Substances 0.000 description 37
- 229940045513 CTLA4 antagonist Drugs 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 31
- 108091033319 polynucleotide Proteins 0.000 description 30
- 102000040430 polynucleotide Human genes 0.000 description 30
- 239000002157 polynucleotide Substances 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 28
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 27
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 27
- 241001529936 Murinae Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 230000000903 blocking effect Effects 0.000 description 26
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 25
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 24
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 24
- 238000013461 design Methods 0.000 description 23
- 210000004408 hybridoma Anatomy 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 22
- 108010002350 Interleukin-2 Proteins 0.000 description 20
- 102000000588 Interleukin-2 Human genes 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 125000003729 nucleotide group Chemical class 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 19
- 241000894007 species Species 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 241001515942 marmosets Species 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000001155 isoelectric focusing Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000002864 sequence alignment Methods 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 231100000617 superantigen Toxicity 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000004940 costimulation Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- -1 B7-2 Proteins 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 241000288906 Primates Species 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 7
- 238000009510 drug design Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000002637 immunotoxin Effects 0.000 description 6
- 231100000608 immunotoxin Toxicity 0.000 description 6
- 229940051026 immunotoxin Drugs 0.000 description 6
- 239000002596 immunotoxin Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 101710146739 Enterotoxin Proteins 0.000 description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 239000000147 enterotoxin Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 108010045634 B7 Antigens Proteins 0.000 description 4
- 102000005738 B7 Antigens Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101001039696 Homo sapiens Lysophospholipid acyltransferase 7 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 4
- 238000012452 Xenomouse strains Methods 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940124691 antibody therapeutics Drugs 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000012933 kinetic analysis Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 230000017274 T cell anergy Effects 0.000 description 2
- 238000003314 affinity selection Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 102000007588 cdc25 Phosphatases Human genes 0.000 description 2
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229940116886 human interleukin-6 Drugs 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000013038 irreversible inhibitor Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ZRHPMMZWDWMKPD-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]imidazol-4-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)N1C=NC(C[C@H](NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)C(O)=O)=C1 ZRHPMMZWDWMKPD-QFIPXVFZSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- QTWZCODKTSUZJN-LJAQVGFWSA-N (2s)-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C(C(C)=C1C)=C(C)C2=C1OC(C)(C)CC2 QTWZCODKTSUZJN-LJAQVGFWSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical compound C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091005769 Clathrin adaptor proteins Proteins 0.000 description 1
- 102000035183 Clathrin adaptor proteins Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102220521138 Dihydrofolate reductase_V21A_mutation Human genes 0.000 description 1
- 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150024013 FRI gene Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000914680 Homo sapiens Fanconi anemia group C protein Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000992170 Homo sapiens Oncostatin-M Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 102220550734 Microtubule-associated tumor suppressor 1_Q75K_mutation Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000005622 Spartium junceum Species 0.000 description 1
- 235000007235 Spartium junceum Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000011111 UV-scan method Methods 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000020996 boneless meat Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000001970 congenital sucrase-isomaltase deficiency Diseases 0.000 description 1
- 239000013632 covalent dimer Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000043703 human OSM Human genes 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 229940124633 peptidic drug Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102200056507 rs104894175 Human genes 0.000 description 1
- 102200009943 rs116840808 Human genes 0.000 description 1
- 102220044166 rs187134574 Human genes 0.000 description 1
- 102220165148 rs191344898 Human genes 0.000 description 1
- 102220172709 rs201384449 Human genes 0.000 description 1
- 102200038213 rs767568897 Human genes 0.000 description 1
- 102220155295 rs886061561 Human genes 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000010572 single replacement reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11364798P | 1998-12-23 | 1998-12-23 | |
PCT/US1999/030895 WO2000037504A2 (en) | 1998-12-23 | 1999-12-23 | Human monoclonal antibodies to ctla-4 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20013147D0 NO20013147D0 (no) | 2001-06-22 |
NO20013147L NO20013147L (no) | 2001-08-23 |
NO332618B1 true NO332618B1 (no) | 2012-11-19 |
Family
ID=22350712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013147A NO332618B1 (no) | 1998-12-23 | 2001-06-22 | Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav |
NO20120398A NO337037B1 (no) | 1998-12-23 | 2012-03-30 | Humane monoklonale antistoff mot CTLA-4 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20120398A NO337037B1 (no) | 1998-12-23 | 2012-03-30 | Humane monoklonale antistoff mot CTLA-4 |
Country Status (41)
Country | Link |
---|---|
EP (3) | EP1141028B1 (pl) |
JP (2) | JP3793693B2 (pl) |
KR (3) | KR100849443B1 (pl) |
CN (1) | CN1328571B (pl) |
AP (1) | AP1590A (pl) |
AT (1) | ATE458008T1 (pl) |
AU (1) | AU772676B2 (pl) |
BG (1) | BG65899B1 (pl) |
BR (2) | BRPI9916853B8 (pl) |
CA (1) | CA2356215C (pl) |
CR (2) | CR6425A (pl) |
CU (1) | CU23292B7 (pl) |
CY (1) | CY1121451T1 (pl) |
CZ (2) | CZ302706B6 (pl) |
DE (1) | DE69942037D1 (pl) |
DK (2) | DK1141028T3 (pl) |
EA (1) | EA006972B1 (pl) |
EE (1) | EE05483B1 (pl) |
ES (2) | ES2706547T3 (pl) |
GE (1) | GEP20053594B (pl) |
HK (1) | HK1041274B (pl) |
HR (2) | HRP20010551B1 (pl) |
HU (2) | HU1300750D0 (pl) |
ID (1) | ID29991A (pl) |
IL (2) | IL143797A0 (pl) |
IS (2) | IS2798B (pl) |
LT (1) | LT2112166T (pl) |
MX (1) | MXPA01006422A (pl) |
NO (2) | NO332618B1 (pl) |
NZ (1) | NZ512553A (pl) |
OA (1) | OA11917A (pl) |
PL (2) | PL210435B1 (pl) |
PT (2) | PT1141028E (pl) |
RS (1) | RS51309B (pl) |
SG (2) | SG143018A1 (pl) |
SI (2) | SI1141028T1 (pl) |
SK (2) | SK288057B6 (pl) |
TR (2) | TR200101831T2 (pl) |
UA (1) | UA76936C2 (pl) |
WO (1) | WO2000037504A2 (pl) |
ZA (1) | ZA200105742B (pl) |
Families Citing this family (454)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02001911A (es) * | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
TW201305214A (zh) | 2000-02-10 | 2013-02-01 | Abbott Gmbh & Co Kg | 與人類間白素-18結合之抗體,及其製法及用途 |
WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
DZ3494A1 (fr) | 2001-01-05 | 2002-07-11 | Pfizer | Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline |
CA2715570A1 (en) | 2001-04-26 | 2002-11-07 | Biogen Idec Ma Inc. | Cripto blocking antibodies and uses thereof |
EP1463522A4 (en) | 2001-05-16 | 2005-04-13 | Einstein Coll Med | HUMAN ANTI-PNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
NZ530765A (en) * | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AU2006228095B2 (en) * | 2001-10-11 | 2010-11-04 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2003220525A1 (en) | 2002-03-29 | 2003-10-20 | Abgenix, Inc. | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
JP2005529873A (ja) * | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
WO2004029069A2 (en) * | 2002-09-30 | 2004-04-08 | Pfizer Products Inc. | Hybridomas producing high levels of human sequence antibody |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
JP2007528721A (ja) * | 2003-08-14 | 2007-10-18 | ダイアックス コーポレイション | エンドセリアーゼ−2リガンド |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
JP4315982B2 (ja) | 2004-01-09 | 2009-08-19 | ファイザー インコーポレイティッド | MAdCAMに対する抗体 |
BRPI0509274A (pt) * | 2004-03-26 | 2007-09-04 | Pfizer Prod Inc | usos de anticorpos anti-ctla-4 |
US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
JP5112863B2 (ja) | 2004-07-01 | 2013-01-09 | ノヴォ ノルディスク アー/エス | ヒト抗−kir抗体 |
MX2007000610A (es) | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina. |
EP1814988A2 (en) * | 2004-11-26 | 2007-08-08 | Pieris AG | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
AU2014240252B2 (en) * | 2005-03-08 | 2016-10-06 | Pfizer Products Inc | Anti-CTLA-4 Antibody Compositions |
AU2012200203B2 (en) * | 2005-03-08 | 2014-07-03 | Pfizer Products Inc. | Anti-CTLA-4 Antibody Compositions |
US20090238820A1 (en) * | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
JP2006265155A (ja) * | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
JP2006265244A (ja) * | 2005-03-23 | 2006-10-05 | Pfizer Prod Inc | Ctla4抗体とホルモン治療を用いた前立腺癌の治療 |
DK2343320T3 (da) | 2005-03-25 | 2018-01-29 | Gitr Inc | Anti-gitr-antistoffer og anvendelser deraf |
DOP2006000093A (es) | 2005-04-25 | 2007-01-31 | Pfizer | Anticuerpos contra miostatina |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
JP5224707B2 (ja) * | 2005-04-28 | 2013-07-03 | 持田製薬株式会社 | 抗血小板膜糖蛋白質viモノクローナル抗体 |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
MX349137B (es) | 2005-06-08 | 2017-07-13 | Dana-Farber Cancer Inst | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
EA200800268A1 (ru) * | 2005-07-07 | 2008-06-30 | Коли Фармасьютикал Груп, Инк. | КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ |
CN100443503C (zh) * | 2005-07-18 | 2008-12-17 | 四川大学华西医院 | 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素 |
EP2500355A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
PT2447283E (pt) | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP1928905B1 (de) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
EP1948214A4 (en) | 2005-11-08 | 2009-12-30 | Medarex Inc | ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT |
DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
JP2009518446A (ja) | 2005-12-07 | 2009-05-07 | メダレックス インコーポレーティッド | Ctla−4抗体投与量漸増レジメン |
US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
US9868961B2 (en) | 2006-03-30 | 2018-01-16 | The Regents Of The University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
WO2007118214A2 (en) | 2006-04-07 | 2007-10-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antibody compositions and methods for treatment of neoplastic disease |
CN101522717A (zh) | 2006-08-04 | 2009-09-02 | 阿斯利康(瑞典)有限公司 | 针对ErbB2的人抗体 |
SI3339445T1 (sl) | 2006-09-08 | 2020-12-31 | Abbvie Bahamas Ltd. | Beljakovine za vezavo interlevkin-13 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2008112193A1 (en) | 2007-03-12 | 2008-09-18 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
AR065921A1 (es) | 2007-04-02 | 2009-07-08 | Amgen Fremont Inc | Anticuerpos anti-ige |
EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
BRPI0911758A8 (pt) | 2008-05-09 | 2017-10-10 | Abbott Lab | Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos |
EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CA2729949A1 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
WO2010006059A1 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
PE20110774A1 (es) | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
KR101012267B1 (ko) * | 2008-08-29 | 2011-02-08 | 주식회사 세이프로드 | 파손이 방지되는 차선규제봉 및 차선규제봉 시공방법 |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
ES2568509T3 (es) | 2009-01-15 | 2016-04-29 | Adaptive Biotechnologies Corporation | Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales |
EP2403531A4 (en) | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
US8283162B2 (en) | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
HUE033312T2 (en) | 2009-07-20 | 2017-11-28 | Bristol Myers Squibb Co | Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases |
MX2012002605A (es) | 2009-08-29 | 2012-04-02 | Abbott Lab | Proteinas terapeutico de union a dll4. |
BR112012004710A2 (pt) | 2009-09-01 | 2016-08-16 | Abbott Lab | imunoglobulinas de domínio variável duplo e uso das mesmas |
WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
MX2012004415A (es) | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
TW201121568A (en) | 2009-10-31 | 2011-07-01 | Abbott Lab | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
KR101539684B1 (ko) | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Il-1 결합 단백질 |
WO2011146382A1 (en) | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
LT3333188T (lt) | 2010-08-19 | 2022-06-10 | Zoetis Belgium S.A. | Anti-ngf antikūnai ir jų panaudojimas |
PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US9221885B2 (en) * | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
SI2651975T1 (en) | 2010-12-14 | 2018-03-30 | National University Of Singapore | Human monoclonal antibody with specificity for the E protein of denga serotype 1 and its use |
WO2012088094A2 (en) | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
CA2821976A1 (en) | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
CN103857411A (zh) | 2011-07-13 | 2014-06-11 | 阿布维公司 | 使用抗il-13抗体治疗哮喘的方法和组合物 |
WO2013013029A1 (en) | 2011-07-19 | 2013-01-24 | The Board Of Trustees Of The University Of Illinois | Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes |
EP2750768B1 (en) | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
CN104203978A (zh) | 2011-10-24 | 2014-12-10 | 艾伯维股份有限公司 | 针对硬化蛋白的免疫结合剂 |
US9803009B2 (en) | 2011-10-24 | 2017-10-31 | Abbvie Inc. | Immunobinders directed against TNF |
RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
WO2013090635A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
WO2013090633A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
AU2012362326A1 (en) | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against IL-13 and/or IL-17 |
IL297229A (en) | 2012-01-27 | 2022-12-01 | Abbvie Inc | The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells |
US20150110779A1 (en) | 2012-03-15 | 2015-04-23 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
WO2013142796A2 (en) | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
US9534059B2 (en) | 2012-04-13 | 2017-01-03 | Children's Medical Center Corporation | TIKI inhibitors |
SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
CN104470949A (zh) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
CN104364264B (zh) | 2012-06-06 | 2018-07-24 | 硕腾服务有限责任公司 | 犬源化抗ngf抗体和其方法 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
AR091755A1 (es) | 2012-07-12 | 2015-02-25 | Abbvie Inc | Proteinas de union a il-1 |
KR102355959B1 (ko) * | 2012-08-23 | 2022-01-27 | 어젠시스 인코포레이티드 | 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US9550986B2 (en) | 2012-12-21 | 2017-01-24 | Abbvie Inc. | High-throughput antibody humanization |
EP3563836A1 (en) | 2013-03-01 | 2019-11-06 | Astex Pharmaceuticals, Inc. | Drug combinations |
EP3916103A1 (en) | 2013-03-14 | 2021-12-01 | Abbott Laboratories | Hcv core lipid binding domain monoclonal antibodies |
AU2014236309A1 (en) | 2013-03-14 | 2015-10-29 | Ren Liu | Cancer treatment using antibodies that bing cell surface GRP78 |
BR112015023355A8 (pt) | 2013-03-14 | 2018-01-30 | Abbott Lab | antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada. |
EP2968526A4 (en) | 2013-03-14 | 2016-11-09 | Abbott Lab | ANTIGEN-ANTIBODY COMBINATION ASSAY OF HEPATITIS C VIRUS AND METHODS AND COMPOSITIONS FOR USE THEREWITH |
JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質 |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
EP3030575B1 (en) | 2013-08-08 | 2018-07-11 | Cytune Pharma | Il-15 and il-15r-alpha sushi domain based modulokines |
PT3030262T (pt) | 2013-08-08 | 2019-12-11 | Inst Gustave Roussy Igr | Composição farmacêutica de associação |
EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
JP2016535989A (ja) | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
EP3065772A4 (en) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
KR102433464B1 (ko) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | 항-gitr 항체 및 이의 사용 방법 |
SG10201810507WA (en) | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
EP3110447B1 (en) | 2014-09-16 | 2020-04-29 | Synermore Biologics Co., Ltd. | Anti-egfr antibody and uses of same |
CA2964155A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
CN107074976B (zh) * | 2014-11-04 | 2020-10-09 | 北京韩美药品有限公司 | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 |
CN105597090B (zh) * | 2014-11-14 | 2022-08-23 | 中国科学院上海营养与健康研究所 | 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用 |
PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
NZ731633A (en) | 2014-11-21 | 2022-01-28 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
BR112017011538A2 (pt) | 2014-12-04 | 2018-03-13 | Bristol-Myers Squibb Company | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) |
CN104387453A (zh) * | 2014-12-08 | 2015-03-04 | 深圳市同康生物医药有限公司 | 树突状细胞靶向肽及编码基因及应用 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
PT3240801T (pt) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Imunoterapia antitumoral combinada |
US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
AU2016219170B2 (en) * | 2015-02-13 | 2021-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CTLA4 |
WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
EP3273974A4 (en) | 2015-03-26 | 2018-11-07 | Women and Infants Hospital of Rhode Island Inc. | Therapy for malignant disease |
EP3281641B1 (en) | 2015-04-07 | 2020-12-16 | Cytlimic Inc. | Adjuvant for cancer vaccines |
ES2905525T3 (es) | 2015-05-06 | 2022-04-11 | Snipr Tech Ltd | Alteración de poblaciones microbianas y modificación de la microbiota |
WO2016191397A1 (en) | 2015-05-22 | 2016-12-01 | Td2 Inc. | Benzamide and active compound compositions and methods of use |
DK3303395T3 (da) | 2015-05-29 | 2020-01-27 | Abbvie Inc | Anti-cd40-antistoffer og anvendelser deraf |
PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
JP2018526977A (ja) | 2015-06-29 | 2018-09-20 | ザ ロックフェラー ユニヴァーシティ | アゴニスト活性が増強されたcd40に対する抗体 |
CN107949425A (zh) | 2015-06-29 | 2018-04-20 | 百时美施贵宝公司 | 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 |
JP6768722B2 (ja) | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
KR20180036974A (ko) | 2015-07-16 | 2018-04-10 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 면역조절을 이용하는 암의 치료를 위한 신규한 접근법 |
WO2017021913A1 (en) | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
US11594135B2 (en) | 2015-11-02 | 2023-02-28 | Memgen, Inc. | Methods of CD40 activation and immune checkpoint blockade |
WO2017079215A1 (en) | 2015-11-03 | 2017-05-11 | Glycomimetics, Inc. | Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same |
CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
EP3400023A1 (en) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
EA201891983A8 (ru) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | Комбинированная терапия антителами к cd73 |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
KR102413037B1 (ko) | 2016-03-15 | 2022-06-23 | 메르사나 테라퓨틱스, 인코포레이티드 | Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법 |
US20190175748A1 (en) | 2016-03-16 | 2019-06-13 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
EA201892362A1 (ru) | 2016-04-18 | 2019-04-30 | Селлдекс Терапьютикс, Инк. | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения |
WO2017189976A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
US20190298824A1 (en) | 2016-05-04 | 2019-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Albumin-binding immunomodulatory compositions and methods of use thereof |
CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
CA3026054A1 (en) | 2016-05-30 | 2017-12-07 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
RU2758007C2 (ru) | 2016-06-30 | 2021-10-25 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
US20190255165A1 (en) | 2016-09-21 | 2019-08-22 | Amal Therapeutics Sa | Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer |
AU2017335732A1 (en) | 2016-09-27 | 2019-04-04 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
AU2017339858B2 (en) | 2016-10-03 | 2022-02-17 | Abbott Laboratories | Improved methods of assessing GFAP status in patient samples |
US10618962B2 (en) * | 2016-10-10 | 2020-04-14 | Crown Bioscience (Taicang) Inc. | Anti-CTLA4 antibodies |
EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
JP7041136B2 (ja) | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Tusc2免疫療法のための方法および組成物 |
EP3532504A1 (en) | 2016-10-28 | 2019-09-04 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
CN110312523B (zh) * | 2016-11-08 | 2024-04-26 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
US11883430B2 (en) | 2016-11-09 | 2024-01-30 | Musc Foundation For Research Development | CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy |
US10780080B2 (en) | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
CA3045243A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
BR112019011370A2 (pt) | 2016-12-01 | 2019-10-15 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
CA3046293A1 (en) | 2016-12-12 | 2018-06-21 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
WO2018156250A1 (en) * | 2017-02-21 | 2018-08-30 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
EP3586136B1 (en) | 2017-02-24 | 2023-11-08 | Board Of Regents, The University Of Texas System | Assay for detection of early stage pancreatic cancer |
TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
EP3366703B1 (en) | 2017-02-28 | 2019-04-03 | Ralf Kleef | Immune checkpoint therapy with hyperthermia |
WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
JP7346300B2 (ja) | 2017-03-23 | 2023-09-19 | アボット・ラボラトリーズ | 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 |
WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
WO2018191531A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
KR20190141223A (ko) | 2017-04-26 | 2019-12-23 | 브리스톨-마이어스 스큅 컴퍼니 | 디술피드 결합 환원을 최소화하는 항체 생산 방법 |
WO2018200823A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
BR112019023992A2 (pt) * | 2017-05-19 | 2020-06-16 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado |
CN108948194B (zh) * | 2017-05-19 | 2023-02-17 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
KR20200013241A (ko) | 2017-05-25 | 2020-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
US10866251B2 (en) | 2017-05-25 | 2020-12-15 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
US11129564B2 (en) | 2017-05-30 | 2021-09-28 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I |
MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
MX2019012038A (es) | 2017-05-30 | 2019-11-18 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. |
JP2020523018A (ja) | 2017-06-09 | 2020-08-06 | プロビデンス ヘルス アンド サービシーズ−オレゴン | がんの処置のための腫瘍反応性ヒトt細胞の同定のためのcd39およびcd103の使用 |
JP7454945B2 (ja) | 2017-07-03 | 2024-03-25 | アボット・ラボラトリーズ | 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法 |
CN111032694B (zh) | 2017-07-14 | 2024-03-08 | 辉瑞大药厂 | 针对madcam的抗体 |
NZ761519A (en) | 2017-07-14 | 2023-07-28 | Innate Tumor Immunity Inc | Nlrp3 modulators |
TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
KR20200074214A (ko) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
JP7344801B2 (ja) | 2017-12-09 | 2023-09-14 | アボット・ラボラトリーズ | グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法 |
WO2019112860A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
RU2756100C1 (ru) * | 2017-12-20 | 2021-09-28 | Харбор Байомед (Шанхай) Ко., Лтд | Антитела, связывающие ctla-4, и их применение |
CN111757757A (zh) | 2017-12-21 | 2020-10-09 | 梅尔莎纳医疗公司 | 吡咯并苯并二氮呯抗体共轭物 |
EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
CN111886255A (zh) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
CA3088542A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
JP2021517589A (ja) | 2018-03-12 | 2021-07-26 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
CN112218892B (zh) * | 2018-03-19 | 2023-04-25 | 上海药明生物技术有限公司 | 新型抗ctla-4抗体多肽 |
CN111971304A (zh) | 2018-03-21 | 2020-11-20 | 戊瑞治疗有限公司 | 在酸性pH结合至VISTA的抗体 |
TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
EP4066851A1 (en) | 2018-03-25 | 2022-10-05 | SNIPR Biome ApS. | Treating & preventing microbial infections |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
US20210361655A1 (en) | 2018-03-27 | 2021-11-25 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
CN112105645A (zh) | 2018-04-18 | 2020-12-18 | Xencor股份有限公司 | Il-15/il-15ra异二聚体fc融合蛋白及其用途 |
MX2020011234A (es) | 2018-04-25 | 2020-11-11 | Innate Tumor Immunity Inc | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). |
EP3810109A4 (en) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING CD73 |
EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
JP2022513421A (ja) | 2018-07-11 | 2022-02-08 | ファイブ プライム セラピューティクス, インコーポレイテッド | 酸性pHでVISTAと結合する抗体 |
SG11202100023XA (en) | 2018-07-11 | 2021-01-28 | Actym Therapeutics Inc | Engineered immunostimulatory bacterial strains and uses thereof |
MX2021000745A (es) | 2018-07-20 | 2021-03-26 | Surface Oncology Inc | Composiciones anti-cd112r y metodos. |
KR20210046023A (ko) | 2018-08-16 | 2021-04-27 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제 |
CN112996567A (zh) | 2018-08-16 | 2021-06-18 | 先天肿瘤免疫公司 | 咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂 |
US11572360B2 (en) | 2018-08-16 | 2023-02-07 | Innate Tumor Immunity, Inc. | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
WO2020048942A1 (en) | 2018-09-04 | 2020-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses |
US20220073638A1 (en) | 2018-09-19 | 2022-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
TWI791894B (zh) | 2018-09-21 | 2023-02-11 | 大陸商信達生物製藥(蘇州)有限公司 | 新型白介素2及其用途 |
WO2020057645A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
US11377477B2 (en) | 2018-10-12 | 2022-07-05 | Xencor, Inc. | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof |
CN112912403A (zh) | 2018-10-23 | 2021-06-04 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
US11274150B2 (en) | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
EP3883955A1 (en) | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
US20220018828A1 (en) | 2018-11-28 | 2022-01-20 | Inserm (Institut National De La Santé Et La Recherche Médicale | Methods and kit for assaying lytic potential of immune effector cells |
CA3121027A1 (en) | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
US20220033778A1 (en) | 2018-11-29 | 2022-02-03 | Board Of Regents, The University Of Texas System | Methods for ex vivo expansion of natural killer cells and use thereof |
US20220018835A1 (en) | 2018-12-07 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
AU2019396360A1 (en) | 2018-12-11 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors |
EP3897624A1 (en) | 2018-12-17 | 2021-10-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of sulconazole as a furin inhibitor |
MX2021007860A (es) | 2018-12-28 | 2021-10-26 | Transgene | Poxvirux deficiente en m2. |
JP7335341B2 (ja) | 2019-01-14 | 2023-08-29 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Nlrp3モジュレーター |
JP7373571B2 (ja) | 2019-01-14 | 2023-11-02 | イネイト・テューマー・イミュニティ・インコーポレイテッド | がん治療に用いるためのnlrp3モジュレーターとしての置換キナゾリン |
WO2020150116A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
ES2930151T3 (es) | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
KR20210121077A (ko) | 2019-01-15 | 2021-10-07 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도 |
WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
US20220143161A1 (en) | 2019-03-13 | 2022-05-12 | Etherna Immunotherapies Nv | Mrna vaccine |
KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
JP2022526960A (ja) | 2019-03-28 | 2022-05-27 | ブリストル-マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
EP3952850A1 (en) | 2019-04-09 | 2022-02-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer |
WO2020212484A1 (en) | 2019-04-17 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
US20220220440A1 (en) | 2019-05-09 | 2022-07-14 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
EP3968971A1 (en) | 2019-05-17 | 2022-03-23 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
WO2020247973A1 (en) | 2019-06-03 | 2020-12-10 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
JP2022535816A (ja) | 2019-06-03 | 2022-08-10 | ザ・ユニバーシティ・オブ・シカゴ | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
US11246906B2 (en) | 2019-06-11 | 2022-02-15 | Alkermes Pharma Ireland Limited | Compositions and methods for subcutaneous administration of cancer immunotherapy |
BR112021025170A2 (pt) | 2019-06-27 | 2022-01-25 | Etherna Immunotherapies Nv | Terapia de combinação |
AU2020298572A1 (en) | 2019-07-02 | 2021-11-18 | Fred Hutchinson Cancer Center | Recombinant Ad35 vectors and related gene therapy improvements |
CN114174337A (zh) | 2019-07-15 | 2022-03-11 | 英特维特国际股份有限公司 | 针对犬ctla-4的犬源化抗体 |
US20220251209A1 (en) | 2019-07-15 | 2022-08-11 | Intervet Inc. | Caninized antibodies to human ctla-4 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
JPWO2021024742A1 (pl) * | 2019-08-06 | 2021-02-11 | ||
AU2020349516A1 (en) | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted imidazole carboxamides and their use in the treatment of medical disorders |
CN114761386A (zh) | 2019-09-17 | 2022-07-15 | 比亚尔R&D投资股份公司 | 作为酸性神经酰胺酶抑制剂的经取代n-杂环甲酰胺及其作为药物的用途 |
KR20220100860A (ko) | 2019-09-17 | 2022-07-18 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물 |
JP2022548292A (ja) | 2019-09-19 | 2022-11-17 | ブリストル-マイヤーズ スクイブ カンパニー | 酸性pHでVISTAと結合する抗体 |
JP2022549273A (ja) | 2019-09-22 | 2022-11-24 | ブリストル-マイヤーズ スクイブ カンパニー | Lag-3アンタゴニスト治療のための定量的空間プロファイリング |
WO2021062244A1 (en) | 2019-09-25 | 2021-04-01 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
EP3800201A1 (en) | 2019-10-01 | 2021-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd28h stimulation enhances nk cell killing activities |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
EP4049675A4 (en) | 2019-10-25 | 2023-11-22 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOREGULATOR |
US20220380765A1 (en) | 2019-11-02 | 2022-12-01 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
KR20220093349A (ko) | 2019-11-08 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종에 대한 lag-3 길항제 요법 |
EP4061809A1 (en) | 2019-11-22 | 2022-09-28 | Theravance Biopharma R&D IP, LLC | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
JPWO2021106978A1 (pl) | 2019-11-27 | 2021-06-03 | ||
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
WO2021127554A1 (en) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
US20230058982A1 (en) | 2019-12-27 | 2023-02-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody and use thereof |
MX2022008412A (es) | 2020-01-07 | 2022-08-08 | Univ Texas | Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer. |
WO2021142203A1 (en) | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
CN115397848A (zh) | 2020-02-05 | 2022-11-25 | 拉利玛生物医药公司 | Tat肽结合蛋白及其用途 |
JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | Il-10およびその使用 |
CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
EP4110810A1 (en) | 2020-02-28 | 2023-01-04 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
EP4118118A1 (en) | 2020-03-09 | 2023-01-18 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
EP4126824A1 (en) | 2020-03-31 | 2023-02-08 | Theravance Biopharma R&D IP, LLC | Substituted pyrimidines and methods of use |
EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
WO2021211331A1 (en) | 2020-04-13 | 2021-10-21 | Abbott Point Of Care Inc. | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE |
US20230159586A1 (en) | 2020-04-21 | 2023-05-25 | University Of Rochester | Inhibitors of human epididymus protein 4 |
US20210335467A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
US20230212256A1 (en) | 2020-05-21 | 2023-07-06 | Board Of Regents, The University Of Texas System | T cell receptors with vgll1 specificity and uses thereof |
CN115803062A (zh) | 2020-06-03 | 2023-03-14 | 博泰康医药公司 | 滋养层细胞表面抗原2(trop-2)抗体 |
WO2021245071A1 (en) | 2020-06-03 | 2021-12-09 | Mv Biotherapeutics Sa | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
EP4165041A1 (en) | 2020-06-10 | 2023-04-19 | Theravance Biopharma R&D IP, LLC | Naphthyridine derivatives useful as alk5 inhibitors |
WO2021260675A1 (en) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
JP2023531537A (ja) | 2020-06-30 | 2023-07-24 | メンドゥス・ベスローテン・フェンノートシャップ | 卵巣癌ワクチンでの白血病由来細胞の使用 |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
US20230295146A1 (en) | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
JP2023534987A (ja) | 2020-07-24 | 2023-08-15 | アムジエン・インコーポレーテツド | Sars-cov2スパイクタンパク質に由来する免疫原 |
US20220043000A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Methods and kits for detecting sars-cov-2 protein in a sample |
CN112359052B (zh) * | 2020-08-20 | 2023-01-03 | 山东兴瑞生物科技有限公司 | 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用 |
AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | 肺がんのためのlag-3アンタゴニスト療法 |
US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
MX2023006604A (es) | 2020-12-04 | 2023-06-19 | Tidal Therapeutics Inc | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos. |
CN116601170A (zh) * | 2020-12-10 | 2023-08-15 | 上海药明生物技术有限公司 | 抗p-钙粘蛋白抗体及其用途 |
WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
US20240052044A1 (en) | 2020-12-24 | 2024-02-15 | Vib Vzw | Non-blocking human ccr8 binders |
EP4267617A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Human ccr8 binders |
WO2022136650A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Murine cross-reactive human ccr8 binders |
EP4267105A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
CA3205538A1 (en) | 2021-01-19 | 2022-07-28 | Han XIAO | Bone-specific delivery of polypeptides |
CN116723854A (zh) | 2021-01-22 | 2023-09-08 | 门德斯有限公司 | 肿瘤疫苗接种方法 |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
EP4070799A1 (en) | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions for the improvement of sport performance |
CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
EP4079311A1 (en) | 2021-04-20 | 2022-10-26 | Nuvamid SA | Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
EP4079310A1 (en) | 2021-04-20 | 2022-10-26 | Nuvamid SA | Nmn and derivatives for its use in the treatment of alpha-synucleinopathies |
WO2022223622A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Cd70結合劑、其結合物及其使用方法 |
WO2022245920A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2022266034A1 (en) | 2021-06-14 | 2022-12-22 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
IL309115A (en) | 2021-06-25 | 2024-02-01 | Chugai Pharmaceutical Co Ltd | Anti-CTLA-4 antibodies |
TW202311291A (zh) | 2021-06-25 | 2023-03-16 | 日商中外製藥股份有限公司 | 抗ctla-4抗體的用途 |
WO2023280790A1 (en) | 2021-07-05 | 2023-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023014922A1 (en) | 2021-08-04 | 2023-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
AU2022332285A1 (en) | 2021-08-23 | 2024-02-15 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
AU2022339759A1 (en) | 2021-08-31 | 2024-03-07 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
IL311790A (en) | 2021-10-05 | 2024-05-01 | Chang Hao Ming | Natural killer cells and methods of their use |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
AU2022372894A1 (en) | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
CA3238167A1 (en) | 2021-11-19 | 2023-05-25 | Maria Leia Smith | Gpc3 binding agents, conjugates thereof and methods of using the same |
CA3238936A1 (en) * | 2021-11-24 | 2023-06-01 | Wayne A. Marasco | Antibodies against ctla-4 and methods of use thereof |
AU2022413677A1 (en) | 2021-12-17 | 2024-06-27 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
TW202332687A (zh) | 2021-12-23 | 2023-08-16 | 比利時商eTheRNA免疫治療公司 | 免疫刺激性mrna組成物及其用途 |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023211972A1 (en) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Chimeric antigen receptor modified regulatory t cells for treating cancer |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
US20240002331A1 (en) | 2022-06-08 | 2024-01-04 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
WO2024052356A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024086827A2 (en) | 2022-10-20 | 2024-04-25 | Repertoire Immune Medicines, Inc. | Cd8 t cell targeted il2 |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
DE69331089T2 (de) | 1992-02-18 | 2002-07-18 | Otsuka Kagaku Kk | Beta-Laktam und Cepham Verbindungen und Ihre Herstellung |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
EP0703979B1 (en) | 1993-06-04 | 2000-09-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for treating kaposi's sarcoma with antisense oligonucleotides |
CA2144319A1 (en) | 1993-07-09 | 1995-01-19 | George N. Cox | Recombinant ctla4 polypeptides and methods for making the same |
AU7405294A (en) | 1993-07-26 | 1995-02-20 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP0749323B1 (en) | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
EP1978033A3 (en) * | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
WO1998004281A1 (en) * | 1996-07-26 | 1998-02-05 | Smithkline Beecham Corpration | Improved method of treating immune cell mediated systemic diseases |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
MXPA02001911A (es) * | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
DE602006017460D1 (de) | 2005-03-14 | 2010-11-25 | Omron Tateisi Electronics Co | Programmierbares Steuersystem |
US8209741B2 (en) | 2007-09-17 | 2012-06-26 | Microsoft Corporation | Human performance in human interactive proofs using partial credit |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
1999
- 1999-12-23 CZ CZ20012349A patent/CZ302706B6/cs not_active IP Right Cessation
- 1999-12-23 EA EA200100698A patent/EA006972B1/ru not_active IP Right Cessation
- 1999-12-23 SG SG200305551-4A patent/SG143018A1/en unknown
- 1999-12-23 KR KR1020077015213A patent/KR100849443B1/ko active IP Right Grant
- 1999-12-23 ES ES09007161T patent/ES2706547T3/es not_active Expired - Lifetime
- 1999-12-23 JP JP2000589573A patent/JP3793693B2/ja not_active Expired - Lifetime
- 1999-12-23 EP EP99966644A patent/EP1141028B1/en not_active Expired - Lifetime
- 1999-12-23 PT PT99966644T patent/PT1141028E/pt unknown
- 1999-12-23 NZ NZ512553A patent/NZ512553A/xx not_active IP Right Cessation
- 1999-12-23 MX MXPA01006422A patent/MXPA01006422A/es active IP Right Grant
- 1999-12-23 SG SG200803369-8A patent/SG156547A1/en unknown
- 1999-12-23 EE EEP200100336A patent/EE05483B1/xx unknown
- 1999-12-23 IL IL14379799A patent/IL143797A0/xx active IP Right Grant
- 1999-12-23 AU AU22149/00A patent/AU772676B2/en not_active Expired
- 1999-12-23 RS YUP-455/01A patent/RS51309B/sr unknown
- 1999-12-23 DK DK99966644.9T patent/DK1141028T3/da active
- 1999-12-23 SI SI9931041T patent/SI1141028T1/sl unknown
- 1999-12-23 PL PL349266A patent/PL210435B1/pl unknown
- 1999-12-23 BR BRPI9916853A patent/BRPI9916853B8/pt unknown
- 1999-12-23 ID IDW00200101614A patent/ID29991A/id unknown
- 1999-12-23 SI SI9931084T patent/SI2112166T1/sl unknown
- 1999-12-23 AP APAP/P/2001/002213A patent/AP1590A/en active
- 1999-12-23 PL PL384501A patent/PL214003B1/pl unknown
- 1999-12-23 EP EP18200101.6A patent/EP3553085A1/en not_active Withdrawn
- 1999-12-23 KR KR1020017007965A patent/KR100617337B1/ko active IP Right Grant
- 1999-12-23 TR TR2001/01831T patent/TR200101831T2/xx unknown
- 1999-12-23 LT LTEP09007161.4T patent/LT2112166T/lt unknown
- 1999-12-23 SK SK914-2001A patent/SK288057B6/sk not_active IP Right Cessation
- 1999-12-23 CN CN99813642.5A patent/CN1328571B/zh not_active Expired - Lifetime
- 1999-12-23 WO PCT/US1999/030895 patent/WO2000037504A2/en active Application Filing
- 1999-12-23 GE GE4453A patent/GEP20053594B/en unknown
- 1999-12-23 SK SK5035-2011A patent/SK288274B6/sk not_active IP Right Cessation
- 1999-12-23 TR TR2002/00735T patent/TR200200735T2/xx unknown
- 1999-12-23 KR KR1020057012533A patent/KR100856446B1/ko active IP Right Grant
- 1999-12-23 CZ CZ20110342A patent/CZ303703B6/cs not_active IP Right Cessation
- 1999-12-23 EP EP09007161.4A patent/EP2112166B1/en not_active Expired - Lifetime
- 1999-12-23 AT AT99966644T patent/ATE458008T1/de active
- 1999-12-23 BR BR9916853-7A patent/BR9916853A/pt not_active IP Right Cessation
- 1999-12-23 OA OA00100166A patent/OA11917A/en unknown
- 1999-12-23 DE DE69942037T patent/DE69942037D1/de not_active Expired - Lifetime
- 1999-12-23 PT PT90071614T patent/PT2112166T/pt unknown
- 1999-12-23 CA CA2356215A patent/CA2356215C/en not_active Expired - Lifetime
- 1999-12-23 HU HUP1300750 patent/HU1300750D0/hu not_active Application Discontinuation
- 1999-12-23 UA UA2001075213A patent/UA76936C2/uk unknown
- 1999-12-23 ES ES99966644T patent/ES2340745T3/es not_active Expired - Lifetime
- 1999-12-23 HU HU0104604A patent/HU229566B1/hu unknown
- 1999-12-23 DK DK09007161.4T patent/DK2112166T3/en active
-
2001
- 2001-06-17 IL IL143797A patent/IL143797A/en not_active IP Right Cessation
- 2001-06-22 IS IS5974A patent/IS2798B/is unknown
- 2001-06-22 NO NO20013147A patent/NO332618B1/no not_active IP Right Cessation
- 2001-06-25 CU CU20010147A patent/CU23292B7/es not_active IP Right Cessation
- 2001-07-12 ZA ZA200105742A patent/ZA200105742B/en unknown
- 2001-07-18 CR CR6425A patent/CR6425A/es unknown
- 2001-07-20 BG BG105722A patent/BG65899B1/bg unknown
- 2001-07-20 HR HRP20010551AA patent/HRP20010551B1/hr not_active IP Right Cessation
-
2002
- 2002-04-15 HK HK02102809.5A patent/HK1041274B/zh not_active IP Right Cessation
-
2004
- 2004-09-28 JP JP2004281376A patent/JP2005087215A/ja active Pending
-
2008
- 2008-05-13 CR CR9972A patent/CR9972A/xx unknown
-
2011
- 2011-03-03 IS IS8950A patent/IS8950A/is unknown
-
2012
- 2012-03-30 NO NO20120398A patent/NO337037B1/no not_active IP Right Cessation
-
2013
- 2013-01-29 HR HRP20130077AA patent/HRP20130077A2/hr not_active Application Discontinuation
-
2018
- 2018-12-19 CY CY20181101358T patent/CY1121451T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20120398L (no) | Humane monoklonale antistoff mot CTLA-4 | |
US9963508B2 (en) | Human monoclonal antibodies to CTLA-4 | |
US7824679B2 (en) | Human monoclonal antibodies to CTLA-4 | |
WO1999045031A9 (en) | Cd147 binding molecules as therapeutics | |
NO340445B1 (no) | Humant monoklonalt anti-IFN antistoff eller fragment derav, samt farmasøytisk blanding. | |
CA2619682A1 (en) | Human monoclonal antibodies to ctla-4 | |
AU2006207845A1 (en) | CD147 Binding Molecules as Therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |